Sanofi Canada announced a new option for the emergency treatment of anaphylaxis. AllerjectTM is the first and only ‘talking’ epinephrine auto-injector in Canada. “Sanofi is excited about being able to offer AllerjectTM,” says Jon Fairest, President and CEO of Sanofi Canada. “AllerjectTM is designed to address unmet patient needs and make a positive difference in the lives of those at risk of a severe allergic reaction, and those who care for them.” Although the precise number of people at risk of anaphylaxis is unknown, a recent study found that approximately 7% (or about 2.5 million Canadians) self-report a food allergy. Epinephrine is the drug of choice for the emergency treatment of severe allergic reactions, and is the medicine in the AllerjectTM auto-injector. To help patients and caregivers correctly use the auto-injector, AllerjectTM comes equipped with automated voice instructions (in either English or French) which will guide them step-by-step through the injection process in the event of an emergency.Results of Clinical Study of Type 2 Diabetes Drug Candidate
A clinical study of peptide TT-401 in type 2 diabetic and obese non-diabetic subjects demonstrated significant improvements in glycemic control and reductions in body weight. This five-week proof of concept study enrolled diabetic patients at five dosing levels and non-diabetic obese patients at one dose level. Both groups received five doses over the five week period and diabetic patients also received stable doses of metformin. The patients who received the three highest doses of TT-401 experienced statistically significant reductions in mean fasting plasma glucose relative to placebo. TT-401 demonstrated an acceptable safety and tolerability profile for all doses, with decreased appetite as the most commonly noted adverse side effect.
